TELA Bio Inc TELA.OQ TELA.O is expected to show a rise in quarterly revenue when it reports results on March 24 for the period ending December 31 2025
The Malvern Pennsylvania-based company is expected to report a 19.3% increase in revenue to $21.047 million from $17.65 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for TELA Bio Inc is for a loss of 18 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for TELA Bio Inc is $4.00, about 433.3% above its last closing price of $0.75
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.20 | -0.20 | -0.19 | Beat | 4.5 |
Jun. 30 2025 | -0.18 | -0.18 | -0.22 | Missed | -24.4 |
Mar. 31 2025 | -0.20 | -0.20 | -0.25 | Missed | -27.8 |
Dec. 31 2024 | -0.24 | -0.22 | -0.23 | Missed | -3.2 |
Sep. 30 2024 | -0.42 | -0.40 | -0.42 | Missed | -3.9 |
Jun. 30 2024 | -0.46 | -0.47 | -0.51 | Missed | -8.1 |
Mar. 31 2024 | -0.51 | -0.50 | -0.23 | Beat | 54.1 |
Dec. 31 2023 | -0.42 | -0.43 | -0.53 | Missed | -21.9 |
This summary was machine generated March 20 at 20:44 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments